Valsartan Tablet
Product Images NDC 42291-856

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Valsartan (NDC 42291-856). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

40 (856 30 40mg)

This is a description of a medicine with the NDC code 42291-856.30. Each tablet contains 0 mg of Valsartan, USP. The dosage and administration details are not available. The text mentions keeping the tablets and all drugs out of reach of children. The manufacturer of these tablets is "Aniesl Pharmaceuticals of Y, LLC." The medicine is only manufactured for ARCRE, Push TN 56478, and AVKKRE o Pz SO.*

FDA Label Image

80 (857 90 80mg)

FDA Label Image

160 (858 90 160mg)

This is a description of a medication with the NDC code 42201-858-90. Each tablet contains 160 mg of valsartan. The medication is packaged in a container with 90 tablets. It is manufactured by Amneal Pharmaceuticals of Brookhaven, New York, and it is distributed by AKARE of Pulaski, Tennessee. The container should be stored at a controlled room temperature and protected from moisture. The text includes a note to keep all drugs out of reach of children.*

FDA Label Image

320 (859 90 320mg)

Each tablet of DG 42291-859-00 contains 20mg of Valsartan, USP. These tablets are used in the treatment of hypertension and heart failure. They should be stored at controlled room temperature and tightly closed in their container to protect from moisture. The medication is manufactured by Amneal Pharmaceuticals and distributed by AKARE.*

FDA Label Image

F9674dc4-figure-01 (Valsartan Tablets Usp 1)

FDA Label Image

1 (Valsartan Tablets Usp 2)

The text provides a table showing the percentage of patients in different subgroups in the VALIAN study and how different medications affected mortality. The study evaluated the effects on mortality for patients under and over 65 years old, male and female, Caucasian and Non-Caucasian, and the use of a beta-blocker. The table shows that valsartan favors over captopril in reducing mortality.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.